Search

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim Animal Health Joins Coalition Calling for Greater Broadband Access in Rural Areas

FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa® (dabigatran etexilate mesylate)

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Jardiance® (empagliflozin) analysis reinforces established safety profile

See our Locations

We offer career development opportunities in over 170 locations across the world. Explore some of our featured locations.

R&D - Transforming tomorrow

Manami Tsutsumi, Senior Associate Director in Research & Development describes what it is like working on the cutting edge of pharmaceutical development.

Clinical Studies

Human Health Innovation

Pipeline

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

Consumer Health Data Privacy Statement

This Consumer Health Data Privacy Statement applies to “Consumer Health Data,” as that term has been defined under applicable law.

Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

Ryan Henri Rickards

Ryan Henry Rickards, a senior finance manager for US Animal Health Commercial Controlling team, highlights his career at Boehringer Ingelheim.

Biopharma Contract Manufacturing

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)

Full results from EMPERIAL exercise ability trials presented

Across Cancer Types

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

Work life balance

It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.

Regulatory Affairs

Read more on BI's two-year fellowship within Regulatory Affairs. The Fellow will obtain in-depth and hands-on experience in regulatory strategy.

Boehringer Ingelheim Venture Fund

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers